Press releases

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year....

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday....

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its...

"As a perfect addition to an already extremely positive year for CHEPLAPHARM, we were able to start another large project in 2018 with F....

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose...